First-In-Class Vorasidenib Among Bumper Crop Of New EU Filings

 
• By Neena Brizmohun

Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.

Brain scan
Vorasidenib is being developed for patients with IDH-mutant diffuse glioma • Source: Shutterstock

More from Europe

More from Geography